# Contents

## Part I  Introduction

1  Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development .................. 3  
Zoran Antonijevic

## Part II  Background

2  Clinical Aspects of Pharmaceutical Portfolio Management .............. 19  
Frederic (Rick) Sax, Raymond A. Huml, and Judith Ng-Cashin

3  Drug Development and the Cost of Capital ............................................ 35  
Kraig F. Schulz, Sarah T. Bobulsky, Frank S. David, Nitin R. Patel, and Zoran Antonijevic

4  Investment Considerations for Pharmaceutical Product Portfolios .............................................................. 49  
Raymond A. Huml

5  Challenges of Portfolio Management in Pharmaceutical Development .............................................................. 71  
Charles Persinger

## Part III  Quantitative Methodology

6  Impact of Phase 2b Strategies on Optimization of Drug Development Programs .............................................................. 83  
Zoran Antonijevic, Jim Bolognese, Carl-Fredrik Burman, Christy Chuang-Stein, Chris Jennison, Martin Kimber, Olga Marchenko, Nitin R. Patel, and José Pinheiro
Using Decision Analysis to Support the Design of Clinical Trials Within a Program
Richard Nixon and Blair Ireland

Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications
Jack Kloeber Jr., Alex Stojanovic, and C. Kwon Kim

Maximizing Return on Investment in Phase II Proof-of-Concept Trials
Cong Chen, Robert A. Beckman, and Linda Z. Sun

Portfolio Optimization of Therapies and Their Predictive Biomarkers
Robert A. Beckman and Cong Chen

Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline
Nitin R. Patel and Suresh Ankolekar

Index
Optimization of Pharmaceutical R&D Programs and Portfolios
Design and Investment Strategy
Antonijevic, Z. (Ed.)
2015, VIII, 202 p. 38 illus., 24 illus. in color., Hardcover
ISBN: 978-3-319-09074-0